Healthcare
Lupin Limited Announces European Launch of Biosimilar Ranibizumab
Lupin Limited (LUPIN) announces the European launch of its biosimilar Ranibizumab, expanding access to retinal disease treatment.
Lupin Limited (LUPIN) today announced that its commercial partner, Sandoz, has launched RanluspecTM, Lupin’s biosimilar Ranibizumab, across Europe, excluding Germany. This launch follows the European Commission approval of RanluspecTM in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.
Strategic Milestone
Thierry Volle, President EMEA and Emerging Markets, Lupin, said, “The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region.”
Commitment to Healthcare
“The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems,” said Dr. Cyrus Karkaria, President – Biotech Business, Lupin.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With 15 state-of-the-art manufacturing sites and 6 research centers globally, Lupin is committed to improving patient health outcomes.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Lupin Limited
Lupin Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Lupin drops 22.9% over three months and trades near its 52-week lows. The PEG of 0.12 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. The stock sits at 6% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 19.1% and profits at 131.5% CAGR, with D/E of 0.32. Meanwhile, the stock dips 22.9% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Lupin Limited.
Healthcare
Suven Life Sciences Limited to Present Seven Scientific Posters at Neuroscience 2026
Suven Life Sciences Limited (SUVEN) to present seven scientific posters at Neuroscience 2026, showcasing CNS drug discovery.
Suven Life Sciences Limited (SUVEN) announced its participation in Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN), to be held in Washington, DC, USA, from November 14-18, 2026. The company will present seven scientific posters highlighting its drug discovery and development programs targeting central nervous system (CNS) disorders.
Diverse Portfolio of Drug Candidates
The presentations span a diverse range of therapeutic areas, including Alzheimer’s Disease, Agitation, Schizophrenia, Narcolepsy, Sleep Disorders, Major Depressive Disorder, and Parkinson’s Disease. The posters highlight Suven’s continued progress in advancing innovative drug candidates through clinical and preclinical development.
Key Presentations
Suven will present the following seven posters: SUVN-M8036: A Multimodal Receptor Antagonist That Exhibits Antipsychotic and Anti-Aggressive-Like Effects in Animal Models; SUVN-I6107 (Tenaclidine): Safety, Tolerability, and Pharmacokinetics of a Pure M1 Positive Allosteric Modulator: Results from a First-in-Human Study in Healthy Subjects; SUVN-L1101142: A Novel Muscarinic M4 Positive Allosteric Modulator for the Treatment of Alzheimer’s Disease and Schizophrenia; Samelisant: Efficacy and Safety of an H3 Receptor Inverse Agonist for the Treatment of Narcolepsy With or Without Cataplexy: A Phase 3 Study; SUVN-N9503012: Efficacy of a Selective 5-HT1A Receptor Partial Agonist Intended for the Treatment of L-Dopa-Induced Dyskinesia; Ropanicant (SUVN-911): A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety in Patients with Major Depressive Disorder; Masupirdine (SUVN-502): Baseline Characteristics from a Phase-3 Study in Alzheimer’s Dementia with Agitation.
Suven’s participation at Neuroscience 2026 reflects the breadth and continued progress of its CNS research and development pipeline. The company remains committed to advancing innovative therapies that address significant unmet medical needs, improve outcomes for patients, and create long-term value for the company.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Suven Life Sciences Limited
Suven Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Suven falls 14.9% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 55% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. The stock holds up despite -19.3% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Suven Life Sciences Limited.
Healthcare
Lotus Eye Hospital and Institute Limited (lotuseye) Reports 36% Revenue Growth in Q2 FY 2026-27; Net Profit Increases to ¥43.95 Lakh
Lotus Eye Hospital and Institute Limited (LOTUSEYE) reports a 36% revenue growth in Q2 FY 2026-27, with net profit rising to ¥43.95 lakh.
Lotus Eye Hospital and Institute Limited (LOTUSEYE) has announced its unaudited financial results for the quarter and half year ended September 30, 2026, reporting strong year-on-year growth in revenue and profitability. The company recorded revenue from operations of ¥17.72 crore in Q2 FY 2026-27, registering a growth of approximately 36% compared to ¥13.04 crore in the corresponding quarter of the previous financial year.
Quarterly Performance
The company’s net profit for the quarter stood at ¥43.95 lakh, compared to ¥11.58 lakh in Q2 of the previous financial year. Profit before tax also increased significantly to ¥55.87 lakh from ¥7.30 lakh during the corresponding period.
Half-Year Performance
For the half year ended September 30, 2026, the company reported revenue from operations of ¥34.78 crore, registering a growth of approximately 31% over ¥26.56 crore in the corresponding half year of the previous financial year. The company’s half-yearly net profit increased by approximately 59% to ¥1.05 crore, compared to ¥66.06 lakh in the corresponding period last year. Profit before tax grew by approximately 95% to ¥1.57 crore.
The financial performance reflects the company’s continued revenue growth and improving profitability. The unaudited financial results were reviewed by the audit committee and approved by the board of directors at its meeting held on November 11, 2026. The statutory auditors have conducted a limited review of the results.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Lotus Eye Hospital and Institute Limited
Lotus Eye Hospital and Institute Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.
Lotus falls 8.6% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue contracts at 4.5% CAGR. That signals structural headwinds, not a short-term blip. The stock sits at 18% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 4.5% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 8.6% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Lotus Eye Hospital and Institute Limited.
Healthcare
Jubilant Pharmova Limited (jublpharma) Announces Oral Presentation of Preliminary Phase 1 Clinical Data for Jbi-802
Jubilant Pharmova Limited (JUBLPHARMA) announces preliminary Phase 1 clinical data for JBI-802 presented at 68th ASH Annual Meeting.
Jubilant Therapeutics, a clinical-stage biopharmaceutical company advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced that clinical results from its Phase 1/2 study of JBI-802 have been selected for an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition.
Preliminary Clinical Data
The abstract data from this ongoing Phase 1/2 study show encouraging early evidence of rapid platelet reductions and hematologic control in patients with essential thrombocythemia (ET) and related MPNs. Key findings include all 8 patients who initiated treatment at the 15 mg achieving a >50% platelet reduction or platelet normalization by Week 3, with a median time to response of 15 days.
Upcoming Event
Jubilant will host an event on December 14, 2026, following the oral presentation by Dr. Andrew McQuillan, MBBS, FRACP, FRCPA, to review the Phase 1 data presented at ASH and discuss their clinical implications. The event will be livestreamed, and a replay will be available on the Company’s website.
For more information, visit www.jubilanttx.com.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Jubilant Pharmova Limited
Jubilant Pharmova Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Jubilant moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 48% of its 52-week range with RSI at 49. In other words, neither side has a clear edge right now. Revenue grows at 9.8% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Jubilant Pharmova Limited.
-
Credit Services3 days agoMoneyboxx Finance Limited (moneyboxx): Q2 FY27 Pre-provision Operating Profit Up 79% Yoy and 4x
-
Consumer Cyclical3 days agoWhirlpool of India Limited (whirlpool) Delivers Double Digit Revenue Growth in Q2 Fy26-27
-
Industrials3 days agoPower & Instrumentation (gujarat) Limited (pigl) Q2 FY27: Ebitda Jumps 45%, Orders Surge
-
HIRECT2 days agoHirect Limited Q2 & H1 FY27: Highest-ever Revenue, Strong Business Momentum
-
Consumer Cyclical2 days agoKalyan Jewellers India Limited (kalyankjil) Q2 FY27: Revenue Surpasses Rs 10,300 Crore, PAT Rises 64%
-
Basic Materials2 days agoVishnu Chemicals Limited Q2fy27: Strategic JV with DCX Chrome SAS, Ebitda Grows 10% Yoy
-
Credit Services2 days agoIifl Finance Limited to Raise ₹6,414 Crores ($686 Million) in Major Private Equity Infusion
-
Basic Materials2 days agoJindal Stainless Limited (JSL) Wins 95 Gold and 6 Silver Awards at QCFI Conventions 2026